| Description | Acolbifene hydrochloride binds to estrogen receptors in the body. It is a type of selective estrogen receptor modulator |
| Target activity | ERβ:0.4 nM (IC50, E2-induced transcriptional activity), ERα:2 nM (IC50, E2-induced transcriptional activity) |
| molecular weight | 494.02 |
| Molecular formula | C29H32ClNO4 |
| CAS | 252555-01-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Calvo E, Luu-The V, Belleau P, Martel C, Labrie F. Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland. Breast Cancer Res Treat. 2012 Jul;134(2):625-47. doi: 10.1007/s10549-012-2104-7. Epub 2012 Jun 8. PubMed PMID: 22678160. 2. Gutman M, Couillard S, Roy J, Labrie F, Candas B, Labrie C. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer. 2002 May 10;99(2):273-8. PubMed PMID: 11979444. 3. Gajdos C, Jordan VC. Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. Clin Breast Cancer. 2002 Jan;2(4):272-81. Review. PubMed PMID: 11899358. 4. Schafer JI, Liu H, Tonetti DA, Jordan VC. The interaction of raloxifene and the active metabolite of the antiestrogen EM-800 (SC 5705) with the human estrogen receptor. Cancer Res. 1999 Sep 1;59(17):4308-13. PubMed PMID: 10485477. |